{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:51:49Z","timestamp":1790621509255,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"London Regional Cancer Program"},{"name":"Strategic Training Program in Cancer Research and Technology Transfer Program with funds from Canadian Institutes for Health Research"},{"name":"NCI","award":["R01 CA138541-01"],"award-info":[{"award-number":["R01 CA138541-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ygyno.2012.01.048","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T19:00:37Z","timestamp":1328122837000},"page":"441-450","source":"Crossref","is-referenced-by-count":24,"title":["Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity"],"prefix":"10.1016","volume":"125","author":[{"given":"Rohann J.M.","family":"Correa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Komar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica G.K.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milani","family":"Sivapragasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masmudur M.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel E.","family":"DiMattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor G.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.01.048_bb0270","series-title":"Canadian Cancer Statistics","author":"Society CC","year":"2011"},{"issue":"2","key":"10.1016\/j.ygyno.2012.01.048_bb0010","first-page":"255","article-title":"Ovarian surface epithelium: biology, endocrinology, and pathology","volume":"22","author":"Auersperg","year":"2001","journal-title":"Endocr Rev"},{"issue":"32","key":"10.1016\/j.ygyno.2012.01.048_bb0015","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.01.048_bb0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcp.21240","article-title":"Epithelial\u2013mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm","volume":"213","author":"Ahmed","year":"2007","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.01.048_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat Clin Pract"},{"issue":"7","key":"10.1016\/j.ygyno.2012.01.048_bb0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ygyno.2012.01.048_bb0035","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.addr.2009.04.012","article-title":"Advancements in adenoviral based virotherapy for ovarian cancer","volume":"61","author":"Matthews","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0040","first-page":"1696","article-title":"Oncolytic reovirus against ovarian and colon cancer","volume":"62","author":"Hirasawa","year":"2002","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ygyno.2012.01.048_bb0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.cgt.7700823","article-title":"Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer","volume":"12","author":"Myers","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.ygyno.2012.01.048_bb0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2006.09.022","article-title":"Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice","volume":"104","author":"Lin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"39","key":"10.1016\/j.ygyno.2012.01.048_bb0055","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguyen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0275","series-title":"ClinicalTrialsgov identifier: NCT00408590","article-title":"Oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer","year":"2008"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0065","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.20.6.1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.01.048_bb0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res"},{"issue":"7362","key":"10.1016\/j.ygyno.2012.01.048_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2012.01.048_bb0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2010.10.031","article-title":"Oncolytic virotherapy of gynecologic malignancies","volume":"120","author":"Hartkopf","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2012.01.048_bb0085","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/14712598.7.9.1415","article-title":"Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer","volume":"7","author":"Stanford","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.ygyno.2012.01.048_bb0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.01.048_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbapap.2007.08.001","article-title":"The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus","volume":"1784","author":"Werden","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13550280701591526","article-title":"Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells","volume":"13","author":"Barrett","year":"2007","journal-title":"J Neurovirol"},{"issue":"12","key":"10.1016\/j.ygyno.2012.01.048_bb0105","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1073\/pnas.0509341103","article-title":"Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor","volume":"103","author":"Wang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.ygyno.2012.01.048_bb0110","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-07-1214","article-title":"Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin","volume":"67","author":"Lun","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2012.01.048_bb0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.mt.6300348","article-title":"Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo","volume":"16","author":"Stanford","year":"2008","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.ygyno.2012.01.048_bb0120","doi-asserted-by":"crossref","first-page":"12068","DOI":"10.1128\/JVI.00963-09","article-title":"The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells","volume":"83","author":"Werden","year":"2009","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.ygyno.2012.01.048_bb0125","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1128\/JVI.02020-09","article-title":"Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells","volume":"84","author":"Werden","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0130","first-page":"103","article-title":"Myxoma virus tropism in human tumor cells","volume":"8","author":"Sypula","year":"2004","journal-title":"Gene Ther Mol Biol"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0135","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/nprot.2006.328","article-title":"Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients","volume":"1","author":"Shepherd","year":"2006","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.ygyno.2012.01.048_bb0140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/JVI.01633-06","article-title":"M135R is a novel cell surface virulence factor of myxoma virus","volume":"81","author":"Barrett","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0280","series-title":"Current protocols in microbiology Chapter 14:Unit 14A 11","article-title":"Myxoma virus: propagation, purification, quantification, and storage","author":"Smallwood","year":"2010"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1757-2215-3-5","article-title":"Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion","volume":"3","author":"Shepherd","year":"2010","journal-title":"J Ovarian Res"},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2012.01.048_bb0155","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.virusres.2009.05.009","article-title":"Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits","volume":"144","author":"Barrett","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/carcin\/bgr241","article-title":"Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids","volume":"33","author":"Correa","year":"2012","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.ygyno.2012.01.048_bb0165","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/JVI.01408-06","article-title":"Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells","volume":"81","author":"Stanford","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0285","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","article-title":"Multicellular spheroids in ovarian cancer metastases: biology and pathology","volume":"113","author":"Shield","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2012.01.048_bb0175","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2012.01.048_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/5042","article-title":"PIK3CA is implicated as an oncogene in ovarian cancer","volume":"21","author":"Shayesteh","year":"1999","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.ygyno.2012.01.048_bb0185","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"7152","key":"10.1016\/j.ygyno.2012.01.048_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ygyno.2012.01.048_bb0195","first-page":"2095","article-title":"Frequent PTEN\/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors","volume":"58","author":"Obata","year":"1998","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2012.01.048_bb0200","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1074\/mcp.M800313-MCP200","article-title":"Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers","volume":"8","author":"Kuk","year":"2009","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0205","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ymthe.2004.08.015","article-title":"Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies","volume":"10","author":"Jiang","year":"2004","journal-title":"Mol Ther"},{"issue":"24","key":"10.1016\/j.ygyno.2012.01.048_bb0210","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1038\/onc.2010.107","article-title":"Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation","volume":"29","author":"Lane","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2012.01.048_bb0290","doi-asserted-by":"crossref","unstructured":"Bowtell DD The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803\u20138.","DOI":"10.1038\/nrc2946"},{"issue":"7353","key":"10.1016\/j.ygyno.2012.01.048_bb0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ygyno.2012.01.048_bb0225","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ygyno.2012.01.048_bb0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2009.283","article-title":"Intelligent design: combination therapy with oncolytic viruses","volume":"18","author":"Ottolino-Perry","year":"2010","journal-title":"Mol Ther"},{"issue":"2\u20133","key":"10.1016\/j.ygyno.2012.01.048_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cytogfr.2010.02.008","article-title":"United virus: the oncolytic tag-team against cancer!","volume":"21","author":"Le Boeuf","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"10.1016\/j.ygyno.2012.01.048_bb0240","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"issue":"44","key":"10.1016\/j.ygyno.2012.01.048_bb0245","doi-asserted-by":"crossref","first-page":"18874","DOI":"10.1073\/pnas.1012667107","article-title":"Mullerian inhibiting substance preferentially inhibits stem\/progenitors in human ovarian cancer cell lines compared with chemotherapeutics","volume":"107","author":"Wei","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ygyno.2012.01.048_bb0295","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"issue":"30","key":"10.1016\/j.ygyno.2012.01.048_bb0255","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","article-title":"Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness","volume":"103","author":"Szotek","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1016\/j.ygyno.2012.01.048_bb0260","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1073\/pnas.1005529108","article-title":"Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells","volume":"108","author":"Stewart","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2\u20133","key":"10.1016\/j.ygyno.2012.01.048_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cytogfr.2010.02.010","article-title":"Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus","volume":"21","author":"Rahman","year":"2010","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:25:23Z","timestamp":1543235123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0090825812000819"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.01.048","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}